←Fibromyalgia
Study register · detail Systematic Review · Fibromyalgia · 2024

Effectiveness and safety of cannabis-based products for medical use in patients with fibromyalgia syndrome: A systematic review

Lopera et al. ·Мир науки, культуры, образования
Mixed GRADE High 0 citations
Samplek = 19 Studien
EndpointPain intensity / quality of…
Blindingunklar
DesignSystematic Review
Key finding

CBPMs and CBMs show potential efficacy for pain, quality of life and sleep in FMS, but the evidence base is limited and methodologically heterogeneous.

Summary

Systematic review of cannabis-based products (CBPMs) and medicines (CBMs) in fibromyalgia; k=19 publications included (up to April 2024). General improvement in pain, quality of life and sleep; no serious adverse events. Evidence limited, need for high-quality studies.

P
PopulationAdults with fibromyalgia syndrome (FMS)
I
InterventionCannabis-based products for medical use (CBPMs) and cannabis-based medicines (CBMs), various substances and forms of application
O
OutcomeGeneral improvement in pain, quality of life and sleep; no serious adverse events reported
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Mixed
Citations / year ★★★★★
Authors
Lopera V, Restrepo JC, Amariles P
DOI 10.1016/j.rcsop.2024.100524↗
Design: Systematic Review
Share
Indication
Further studies on Fibromyalgia
All studies →
S Rasmussen et al. · 2026 · Annals of the rheumatic diseases
1 citations
Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
Harm RCT

n=200 Fibromyalgie-Patienten, CBD 50 mg täglich vs. Placebo über 24 Wochen; primärer Endpunkt Schmerzintensität (NRS): CBD-Gruppe -0,4 Punkte (95% CI: -0,82 bis 0,08), Placebo-Gruppe -1,1 Punkte (95% CI: -1,53 bis -0,63), Gruppenunterschied -0,7 Punkte (95% CI: -1,2 bis -0,25; p=0,0028) zugunsten Placebo. CBD 50 mg täglich zeigte keine analgetische Wirksamkeit.

10.1016/j.ard.2025.07.008 View study →
S Walitt et al. · 2016 · Cochrane Database of Systematic Reviews
120 citations
Cannabinoids for fibromyalgia
No benefit demonstrated Cochrane Review

Cochrane SR über 2 RCTs (n=72) zu Cannabinoiden bei Fibromyalgie; nabilone vs. Placebo zeigte keine statistisch signifikante Schmerzreduktion oder Verbesserung der Lebensqualität; sehr kleine Stichprobengröße und kurze Studiendauer limitieren Aussagekraft; keine ausreichende Evidenz für Wirksamkeit.

10.1002/14651858.cd011694.pub2 View study →
A Häuser et al. · 2018 · European Journal of Pain
189 citations
European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management
Unclear Leitlinie

EFIC-Positionspapier zur angemessenen Anwendung cannabisbasierter Medikamente bei chronischen Schmerzen; empfiehlt zurückhaltenden Einsatz bei Fibromyalgie aufgrund begrenzter Evidenz (schwache Empfehlung).

10.1002/ejp.1297 View study →

The impediment to action advances action. — Marcus Aurelius